Epic Sciences’ platform technology has been used in studies on various stages of disease progression across a number of different indications, including prostate, breast and lung cancer.
Current studies in metastatic breast cancer have shown links between genotypic heterogeneity and specific phenotypic profiles. This flexible starting sample has also enabled the demonstration of feasibility in melanoma, pancreatic, ovarian, colorectal, and bladder cancers.
To date, Epic Sciences has identified the co-occurrence of AR+, ER+ and HER2+ CTCs and cellular genomic heterogeneity through extensive single cell phenotypic and genomic profiling of CTCs. We have also observed key genomic alterations that are linked to phenotype.
To learn more about Epic Sciences’ work in your area of interest, download our posters for: